Strategyproof matching with regional minimum and maximum quotas

This paper considers matching problems with individual/regional minimum/maximum quotas. Although such quotas are relevant in many real-world settings, there is a lack of strategyproof mechanisms that take such quotas into account. We first show that without any restrictions on the regional structure, checking the existence of a feasible matching that satisfies all quotas is NP-complete. Then, assuming that regions have a hierarchical structure (i.e., a tree), we show that checking the existence of a feasible matching can be done in time linear in the number of regions. We develop two strategyproof matching mechanisms based on the Deferred Acceptance mechanism (DA), which we call Priority List based Deferred Acceptance with Regional minimum and maximum Quotas (PLDA-RQ) and Round-robin Selection Deferred Acceptance with Regional minimum and maximum Quotas (RSDA-RQ). When regional quotas are imposed, a stable matching may no longer exist since fairness and nonwastefulness, which compose stability, are incompatible. We show that both mechanisms are fair. As a result, they are inevitably wasteful. We show that the two mechanisms satisfy different versions of nonwastefulness respectively; each is weaker than the original nonwastefulness. Moreover, we compare our mechanisms with an artificial cap mechanism via simulation experiments, which illustrate that they have a clear advantage in terms of nonwastefulness and student welfare

Two cases of breast carcinoma with osteoclastic giant cells: Are the osteoclastic giant cells pro-tumoural differentiation of macrophages?

Breast carcinoma with osteoclastic giant cells (OGCs) is characterized by multinucleated OGCs, and usually displays inflammatory hypervascular stroma. OGCs may derive from tumor-associated macrophages, but their nature remains controversial. We report two cases, in which OGCs appear in common microenvironment despite different tumoural histology. A 44-year-old woman (Case 1) had OGCs accompanying invasive ductal carcinoma, and an 83-year-old woman (Case 2) with carcinosarcoma. Immunohistochemically, in both cases, tumoural and non-tumoural cells strongly expressed VEGF and MMP12, which promote macrophage migration and angiogenesis. The Chalkley count on CD-31-stained sections revealed elevated angiogenesis in both cases. The OGCs expressed bone-osteoclast markers (MMP9, TRAP, cathepsin K) and a histiocyte marker (CD68), but not an MHC class II antigen, HLA-DR. The results indicate a pathogenesis: regardless of tumoural histology, OGCs derive from macrophages, likely in response to hypervascular microenvironments with secretion of common cytokines. The OGCs have acquired bone-osteoclast-like characteristics, but lost antigen presentation abilities as an anti-cancer defense. Appearance of OGCs may not be anti-tumoural immunological reactions, but rather pro-tumoural differentiation of macrophage responding to hypervascular microenvironments induced by breast cancer

NBRP, National Bioresource Project of Japan and plant bioresource management

The National BioResource Project has been organized and established to promote research activities using valuable bioresources. A total of twenty-eight bioresources for ten animals, nine plants and nine microorganisms/cell lines developed or collected in Japan were selected for the project. Resources are categorized into several different groups in the project; genetic resources, germplasm, genome resources and their information. Choices of how many resources must be preserved and maintained and in which categories are dependent on the status of the research community of each organism. These resources, if utilized systematically and intelligently, are powerful means for leading new scientific discoveries. Some examples can be seen in this paper. This paper reviews plant bioresources with the main focus on rice resource activities within the project

Diagnostic value of transmural perfusion ratio derived from dynamic CT-based myocardial perfusion imaging for the detection of haemodynamically relevant coronary artery stenosis

Objectives: To investigate the additional value of transmural perfusion ratio (TPR) in dynamic CT myocardial perfusion imaging for detection of haemodynamically significant coronary artery disease compared with fractional flow reserve (FFR). Methods: Subjects with suspected or known coronary artery disease were prospectively included and underwent a CT-MPI examination. From the CT-MPI time-point data absolute myocardial blood flow (MBF) values were temporally resolved using a hybrid deconvolution model. An absolute MBF value was measured in the suspected perfusion defect. TPR was defined as the ratio between the subendocardial and subepicardial MBF. TPR and MBF results were compared with invasive FFR using a threshold of 0.80. Results: Forty-three patients and 94 territories were analysed. The area under the receiver operator curve was larger for MBF (0.78) compared with TPR (0.65, P = 0.026). No significant differences were found in diagnostic classification between MBF and TPR with a territory-based accuracy of 77 % (67-86 %) for MBF compared with 70 % (60-81 %) for TPR. Combined MBF and TPR classification did not improve the diagnostic classification. Conclusions: Dynamic CT-MPI-based transmural perfusion ratio predicts haemodynamically significant coronary artery disease. However, diagnostic performance of dynamic CT-MPI-derived TPR is inferior to quantified MBF and has limited incremental value. Key Points: • The transmural perfusion ratio from dynamic CT-MPI predicts functional obstructive coronary artery disease• Performance of the transmural perfusion ratio is inferior to quantified myocardial blood flow• The incremental value of the transmural perfusion ratio is limite

Evaluación de factibilidad económica y financiera para la importación y comercialización de llantas para vehículos de tres ruedas - 2016

RESUMEN La presente tesis en proyectos de inversión trata del estudio de rentabilidad de la importación y comercialización de llantas para vehículos de tres ruedas en nuestro mercado conocidos como MOTOTAXI especialmente de la marca Bajaj. Contactamos con un fabricante de llantas de la India quien llego a Lima ofreciendo sus productos y en el abanico de su oferta pudimos identificar las llantas para mototaxi, cerramos el negocio por la compra de un contenedor de 20 pies (2 250 llantas) del tamaño 4.00-8. La empresa fue constituida el 29 de septiembre del 2016 con el nombre de JRM TYRES SAC con número de RUC 20601541000 el capital inicial fue de S/. 87 340.00 obtenido a través de un prestamos en el Banco de Crédito del Perú con una TEA de 8.5 %, los socios accionistas son 3 quienes comparten todos los gastos relacionados al proyecto. La demanda en Lima Metropolitana es el 50 % del mercado total en el Perú la diferencia se encuentra distribuida en los demás departamentos del país. No existe una ley que reglamente el servicio que los mototaxis realizan, son las municipales que a través de ordenanzas reglamentan el servicio y la cantidad de estos vehículos. Nuestro producto, no se comercializa en Lima, pero si existen varias marcas que han ingresado al mercado, una de las debilidades es que aún no conocemos exactamente sus cualidades de rendimiento, pero según la información del fabricante estaríamos compitiendo con la llanta mejor posicionada en el mercado local (MRF). Se ha realizado el estudio de rentabilidad del proyecto, dando como resultados la viabilidad del proyecto de inversión, con la meta inicial de importar 4 contenedores de 20 ft por año y comercializar cada contenedor en 3 meses. Para nuestro segundo año esperamos tener posicionada nuestra marca e iniciar actividades en otros rubros, ya que el fabricante tiene un gran abanico de productos.ABSTRACT The present thesis in investment projects is about the studying of the economic profitability of import and selling tyres to three wheeler vehicles in our market, knowing as “mototaxi”, mainly Bajaj brand. We did contact with one maker of this type of tyres from India who arrived to Lima offering his products and we can found the three wheeler tyres is their product catalog, we close a business for the purchase of one (20 feet) container (2 250 units) of 4.00 – 8 tyres. The business was establish in September 29th, 2016 under the name of JRM TYRES SAC, with RUC number 20601541000, our initial capital was S/. 127 340 obtained by bank loan in the Bank of Credit of Peru (BCP) with an interest of TEA of 8.5 %, the shareholder partners are three people whom they face all the expenses of the project. The demand in Lima area is 50% of the global market in Peru, the other 50% is located around the others departments of Peru. There is not a law that regulates the service of the mototaxis do; however the municipalities through ordinances are regulate the services and the quantity of these vehicles in each district. Our product is not selling in Lima under the same name and brand, but there are many brands that are entry at the local market. One of our weaknesses is that we do not know exactly their qualities of the performance but according to the manufacturer the tyres are as same as the best tyres in our market (MRF). We did the studies of the cost effectiveness of our project, and the results are positives, with the target of import four containers per year and sell it every three months. For our second year we will hope to have our brand positioned and start other activities of selling different kinds of tyres in other areas, because the manufacturer has a good variety of products

Mitotic figure recognition: Agreement among pathologists and computerized detector

Abstract. Despite the prognostic importance of mitotic count as one of the components of the Bloom -Richardson grad

First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset

This prespecified subanalysis of the global, randomized controlled phase Ill KEYNOTE-024 study of pembrolizumab vs chemotherapy in previously untreated metastatic non-small-cell lung cancer without EGFR/ALK alterations and a programmed death-ligand 1 (PD-L1) tumor proportion score of 50% or greater evaluated clinical outcomes among patients enrolled in Japan. Treatment consisted of pembrolizumab 200 mg every 3 weeks (35 cycles) or platinum-based chemotherapy (four to six cycles). The primary end-point was progression-free survival; secondary end-points included overall survival and safety. Of 305 patients randomized in KEYNOTE-024 overall, 40 patients were enrolled in Japan (all received treatment: pembrolizumab, n = 21; chemotherapy, n = 19). The hazard ratio (HR) for progression-free survival by independent central review (data cut-off date, 10 July 2017) was 0.25 (95% confidence interval [CI], 0.10-0.64; one-sided, nominal P = .001). The HR for overall survival (data cut-off date, 15 February 2019) was 0.39 (95% CI, 0.17-0.91; one-sided, nominal P = .012). Treatment-related adverse events occurred in 21/21 (100%) pembrolizumab-treated and 18/19 (95%) chemotherapy-treated patients; eight patients (38%) and nine patients (47%), respectively, had grade 3-5 events. Immune-mediated adverse events and infusion reactions occurred in 11 patients (52%) and four patients (21%), respectively; four patients (19%) and one patient (5%), respectively, had grade 3-5 events. Consistent with results from KEYNOTE-024 overall, first-line pembrolizumab improved progression-free survival and overall survival vs chemotherapy with manageable safety among Japanese patients with metastatic non-small-cell lung cancer without EGFRIALK alterations and a PD-L1 tumor proportion score of 50% or greater

First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset

This prespecified subanalysis of the global, randomized controlled phase III KEYNOTE‐024 study of pembrolizumab vs chemotherapy in previously untreated metastatic non‐small‐cell lung cancer without EGFR/ALK alterations and a programmed death ligand 1 (PD‐L1) tumor proportion score of 50% or higher evaluated clinical outcomes among patients enrolled in Japan. Treatment consisted of pembrolizumab 200 mg every 3 weeks (35 cycles) or platinum‐based chemotherapy (four to six cycles). The primary end‐point was progression‐free survival; secondary end‐points included overall survival and safety. Of 305 patients randomized in KEYNOTE‐024 overall, 40 patients were enrolled in Japan (all received treatment: pembrolizumab, n = 21; chemotherapy, n = 19). Median progression‐free survival was 41.4 (95% confidence interval [CI], 4.2‐42.5) months with pembrolizumab and 4.1 (95% CI, 2.8‐8.3) months with chemotherapy (hazard ratio [HR], 0.27 [95% CI, 0.11‐0.65]; one‐sided, nominal P = .001). Median overall survival was not reached (NR) (95% CI, 22.9‒NR) and 21.5 (95% CI, 5.2‐35.0) months, respectively (HR, 0.39 [95% CI, 0.17‐0.91]; one‐sided, nominal P = .012). Treatment‐related adverse events occurred in 21/21 (100%) pembrolizumab‐treated and 18/19 (95%) chemotherapy‐treated patients; eight patients (38%) and nine patients (47%), respectively, had grade 3‐5 events. Immune‐mediated adverse events and infusion reactions occurred in 11 pembrolizumab‐treated patients (52%) and four chemotherapy‐treated patients (21%), respectively; four patients (19%) and one patient (5%), respectively, had grade 3‐5 events. Consistent with results from KEYNOTE‐024 overall, first‐line pembrolizumab improved progression‐free survival and overall survival vs chemotherapy with manageable safety among Japanese patients with metastatic non‐small‐cell lung cancer without EGFR/ALK alterations and a PD‐L1 tumor proportion score of 50% or higher. The trial is registered with Clinicaltrials.gov: NCT02142738